Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes

Vikas S. Sridhar*, Christine P. Limonte, Per Henrik Groop, Hiddo J.L. Heerspink, Richard E. Pratley, Peter Rossing, Jay S. Skyler, David Z.I. Cherney

*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskriftReviewForskningpeer review

7 Citationer (Scopus)

Abstract

Current management of chronic kidney disease (CKD) in type 1 diabetes centres on glycaemic control, renin–angiotensin system inhibition and optimisation of risk factors including blood pressure, lipids and body weight. While these therapeutic approaches have significantly improved outcomes among people with type 1 diabetes and CKD, this population remains at substantial elevated risk for adverse kidney and cardiovascular events, with limited improvements over the last few decades. The significant burden of CKD and CVD in type 1 diabetes populations highlights the need to identify novel therapies with the potential for heart and kidney protection. Over the last decade, sodium–glucose cotransporter-2 inhibitors, glucagon-like peptide 1 receptor agonists and non-steroidal mineralocorticoid receptor antagonists have emerged as potent kidney-protective and/or cardioprotective agents in type 2 diabetes. The consistent, substantial kidney and cardiovascular benefits of these agents has led to their incorporation into professional guidelines as foundational care for type 2 diabetes. Furthermore, introduction of these agents into clinical practice has been accompanied by a shift in the focus of diabetes care from a ‘glucose-centric’ to a ‘cardiorenal risk-centric’ approach. In this review, we evaluate the potential translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes with the lens of preventing the development and progression of CKD.
OriginalsprogEngelsk
TidsskriftDiabetologia
Vol/bind67
Udgave nummer1
Sider (fra-til)3-18
Antal sider16
ISSN0012-186X
DOI
StatusUdgivet - 2024

Bibliografisk note

Funding Information:
VSS is supported by a Department of Medicine Eliot Phillipson Clinician-Scientist Training Program, a Banting and Best Diabetes Centre Postdoctoral Fellowship at the University of Toronto and a Canadian Institutes of Health Research (CIHR) Frederick Banting and Charles Best Canada Graduate Scholarships Doctoral Research Award. CPL is supported by an American Kidney Fund’s Clinical Scientist in Nephrology Award. DZIC is supported by a Department of Medicine, University of Toronto Merit Award and receives support from the CIHR, Diabetes Canada and the Heart & Stroke/Richard Lewar Centre of Excellence in Cardiovascular Research. DZIC is also the recipient of a 5 year CIHR–Kidney Foundation of Canada Team Grant Award. PR is supported by a Novo Nordisk Foundation grant (NNF22OC0077730; ‘Multifactorial intervention to reduce cardiorenal disease in type 1 diabetes – a prospective, randomised, open, multicenter study – the Steno 1 study’). JSS is supported by the Diabetes Research Institute Foundation.

Publisher Copyright:
© 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Citationsformater